Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
39 results about "AXL Protein" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
View/Edit Mouse. Tyrosine-protein kinase receptor UFO is an enzyme that in humans is encoded by the AXL gene. The gene was initially designated as UFO, in allusion to the unidentified function of this protein.
Inhibition of AXL Signaling in Anti-Metastatic Therapy
Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL and its ligand GAS6.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Universal fibronectin type iii binding-domain libraries
Fibronectin Type III (FN3) polypeptide libraries are described, along with their use in identifying fibronectin-type binding peptides having hign binding affinities, e.g., greater than 300 nM, for VEGFR2 or Axl proteins.
Owner:PROTELICA
Inhibition of AXL signaling in anti-metastatic therapy
Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL and its ligand GAS6.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Axl receptor tyrosine kinase aptamer inhibitor for use in therapy
InactiveUS20130197070A1Improve stabilityOrganic active ingredientsSugar derivativesNucleotide AptamersAXL Protein
The present invention concerns a nucleotide aptamer having the sequence: 5′-AUGAUCAAUCGCCUCAAUUCGACAGGAGGCUCAC-3′(SEQ ID NO: 1) for use in the treatment and / or prevention and / or diagnosis of an Axl receptor tyrosine kinase induced disorder and a pharmaceutical composition comprising the same. The invention also relates to a method for the diagnosis of an Axl receptor tyrosine kinase induced disorder in a patient from which a sample is obtained and related diagnostic kit.
Owner:CONSIGLIO NAT DELLE RICERCHE
Inhibition of AXL Signaling in Anti-Metastatic Therapy
Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL and its ligand GAS6.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Axl fusion proteins as Axl tyrosine kinase inhibitors
ActiveUS8168415B2Peptide/protein ingredientsAntibody mimetics/scaffoldsTyrosine-kinase inhibitorCancer therapy
Disclosed are novel inhibitors of the Axl receptor tyrosine kinase (RTK) and methods of using such inhibitors in a variety of therapeutic approaches in the areas of cancer therapy and anti-thrombosis (anti-clotting) therapy.
Owner:UNIV OF COLORADO THE REGENTS OF
Anti-Axl antibodies
Owner:BERGENBIO ASA
Inhibition of AXL signaling in anti-metastatic therapy
Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL and its ligand GAS6.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Antibody targeting AXL and antibody-drug conjugate and preparation method and application thereof
InactiveCN110483639AImprove uniformityImprove stabilityBiological material analysisImmunoglobulins against cell receptors/antigens/surface-determinantsHumanized antibodyAntibody targeting
The invention discloses a novel monoclonal antibody targeting AXL and an antibody-drug conjugate. The invention further discloses a preparation method of the antibody and the antibody-drug conjugate.The AXL antibody can efficiently and highly specifically bind purified human AXL proteins and AXL on the surfaces of various tumor cells. The humanized antibody further has high affinity and low immunogenicity. The AXL antibody-drug conjugate has significant anti-tumor effects on tumor cells with high expression of AXL.
Owner:FUDAN UNIV +1
Anti-axl antagonistic antibodies
ActiveUS20170349658A1Moderate anti-tumor activityBiological material analysisImmunoglobulins against cell receptors/antigens/surface-determinantsAntibodyAXL Protein
Described are antibodies that specifically bind to the Axl protein and inhibit the interaction between Axl and the Axl-ligand, Gas6. Also disclosed are methods for the production and use of the anti-Axl antibodies.
Owner:BERGEN TEKNOLOGIOVERFORIN AS
Kit for detecting premature rupture of membrane by taking Axl as detection index and preparation method thereof
ActiveCN101858917AQuantitative detection of accurate contentImprove accuracyMaterial analysisChromogenic SubstratesMonoclonal antibody
The invention discloses application of a regent for detecting Axl receptor tyrosine kinase to prepare a kit for detecting whether a pregnant woman has a premature rupture of membranes. The regent is a monoclonal antibody of the Axl receptor tyrosine kinase which is labeled by biotin. The kit includes a perforated plate coated with the monoclonal antibody of the Axl receptor tyrosine kinase, biotin-labeled monoclonal antibody detection liquid of the Axl receptor tyrosine kinase, avidin-horse radish peroxidase combined with biotin-labeled monoclonal antibody of the Axl receptor tyrosine kinase, a chromogenic substrate 3',3',5,5'-tetramethylbenzidine, and an Axl protein standard substance. A preparation method for the kit comprises the following steps of: (1) preparing the perforated plate coated with the monoclonal antibody of the Axl receptor tyrosine kinase; (2) preparing the biotin-labeled monoclonal antibody detection liquid of the Axl receptor tyrosine kinase; and (3) preparing avidin-horse radish peroxidase, the chromogenic substrate 3',3',5,5'-tetramethylbenzidine, and the protein standard substance of the Axl receptor tyrosine kinase.
Owner:ORIGISSAY BIOLOGICS TECH
Anti-axl antibodies
Antibodies characterized by their variable sequences / CDRs which specifically bind to the Axl protein are described. Also disclosed are methods for the production and use of the anti-Axl antibodies.
Owner:BERGENBIO ASA
Antibodies that bind to AXL proteins
ActiveUS10787517B2Biological material analysisImmunoglobulins against cell receptors/antigens/surface-determinantsAbnormal expressionAntiendomysial antibodies
Antibodies that bind to AXL protein and variants thereof are described herein. AXL exhibits a distinct and limited expression pattern in normal adult tissue(s), and is aberrantly expressed in the cancers listed in Table I. Consequently, the MAbs of the invention provide a diagnostic composition for the treatment and management of cancer.
Owner:AGENSYS
Natural killer cell compositions and method for production of the same
InactiveCN101258160AImprove transfer efficiencyImprove cancer killing efficiencyPeptidesFlt3 ligandPrecursor Natural Killer Cell
The present invention relates to a ligand of AxI receptor tyrosine kinase used to induce the differentiation from precursor natural killer cell to mature natural killer-cell. In addition, it relates to a process for producing mature natural killer cell comprising treating hematopoietic stem cell with interleukin-7, stem cell factor and Flt3L to differentiate into precursor natural killer cell, and treating the resulting precursor natural killer cell with ligand of AxI receptor tyrosine kinase to produce mature natural killer cell.
Owner:IND FOUND OF CHONNAM NAT UNIV +1
Antibodies that bind to AXL proteins
ActiveUS10787516B2Biological material analysisImmunoglobulins against cell receptors/antigens/surface-determinantsAbnormal expressionAntiendomysial antibodies
Antibodies that bind to AXL protein and variants thereof are described herein. AXL exhibits a distinct and limited expression pattern in normal adult tissue(s), and is aberrantly expressed in the cancers listed in Table I. Consequently, the MAbs of the invention provide a diagnostic composition for the treatment and management of cancer.
Owner:AGENSYS +1
Monoclonal antibody specially combined with AXL
ActiveCN107759691AHigh affinityNo side effectsImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsAntigenAntigen Binding Fragment
The invention discloses a monoclonal antibody specially combined with AXL or an antigen combined segment thereof. The monoclonal antibody can be specifically combined with an AXL protein. The antibodydisclosed by the invention can be used for preventing and treating diseases induced by overexpression of the AXL protein, and has a wide application prospect clinically.
Owner:SUMGEN MAB BEIJING BIOTECH CO LTD
Universal fibronectin type III binding-domain libraries
Fibronectin Type III (FN3) polypeptide libraries are described, along with their use in identifying fibronectin-type binding peptides having high binding affinities, e.g., greater than 300 nM, for VEGFR2 or Axl proteins.
Owner:PROTELICA
Substituted quinolone derivatives, or pharmaceutically acceptable salts or stereoisomers thereof, and pharmaceutical compositions and use thereof
Provided are a substituted quinolone derivative as shown by formula (I), or a pharmaceutically acceptable salt and a prodrug molecule thereof, and a pharmaceutical composition thereof, as well as the use of same in preparing drugs for the prevention and treatment of a tumor. The quinolone derivative, salt, prodrug molecule, and pharmaceutical composition thereof can be used as a protein kinase inhibitor, which is effective in inhibiting the activity of AXL protein kinase, and is capable of inhibiting the proliferation, migration and invasion of various tumor cells; and can be used in the preparation of anti-tumor drugs, especially drugs for treating hyperproliferative diseases such as a tumor in human beings and other mammals.
Owner:SHANGHAI HAIHE PHARMACEUTICAL CO LTD
Modulation of AXL receptor activity in combination with cytoreductive therapy
InactiveUS20180140679A1Enhance anti-proliferative effectImprove effectivenessPeptide/protein ingredientsTransferasesCancer researchAXL Protein
Compositions and methods are provided for treating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits AXL protein activity, for example by inhibition of the binding interaction between AXL and its ligand GAS6. The treatment may be combined with a cytoreductive therapy.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Methods of treating metastatic cancers using axl decoy receptors
PendingUS20200289613A1High indexCombination is synergisticOrganic active ingredientsCell receptors/surface-antigens/surface-determinantsDecoy receptorsPharmaceutical drug
Compositions and methods are provided for treating a human metastatic cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits AXL protein activity, for example by inhibition of the binding interaction between AXL and its ligand GAS6.
Owner:ARAVIVE BIOLOGICS INC
Antibodies that bind to axl proteins
ActiveUS20180134793A1Biological material analysisImmunoglobulins against cell receptors/antigens/surface-determinantsCancer researchAntibody
Antibodies that bind to AXL protein and variants thereof are described herein. AXL exhibits a distinct and limited expression pattern in normal adult tissue(s), and is aberrantly expressed in the cancers listed in Table I. Consequently, the MAbs of the invention provide a diagnostic composition for the treatment and management of cancer.
Owner:AGENSYS
Anti-axl antibodies, antibody fragments and their immunoconjugates and uses thereof
ActiveUS20190177417A1Immunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsHeavy chainAntibody fragments
A polypeptide having a heavy chain variable region and / or light chain variable region that specifically binds to Axl protein as well as antibodies and antibody fragments containing the heavy chain variable region and / or the light chain variable region that bind to Axl protein. Pharmaceutical compositions and kits comprising the polypeptide or antibodies and antibody fragments containing the polypeptide are also provided.
Owner:BIOATLA INC
Anti-Axl antagonistic antibodies
ActiveUS10208121B2Biological material analysisImmunoglobulins against cell receptors/antigens/surface-determinantsAntibodyAXL Protein
Owner:BERGEN TEKNOLOGIOVERFORING AS
Antibodies that bind to axl proteins
ActiveUS20210188984A1Biological material analysisImmunoglobulins against cell receptors/antigens/surface-determinantsAbnormal expressionAntiendomysial antibodies
Antibodies that bind to AXL protein and variants thereof are described herein. AXL exhibits a distinct and limited expression pattern in normal adult tissue(s), and is aberrantly expressed in the cancers listed in Table I. Consequently, the MAbs of the invention provide a diagnostic composition for the treatment and management of cancer.
Owner:AGENSYS INC
Anti-Axl antibodies, antibody fragments and their immunoconjugates and uses thereof
ActiveUS11149088B2Immunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsAntiendomysial antibodiesHeavy chain
Owner:BIOATLA LLC
Antibody targeting AXL protein, antigen binding fragment thereof, preparation method and application thereof
ActiveCN113444180AReduce tissue toxicityImprove securityTransferasesBlood/immune system cellsAntigen Binding FragmentAntigen binding
The invention provides an antibody targeting AXL protein or an antigen binding fragment thereof, a preparation method and application thereof. The invention also provides isolated polynucleotides encoding the antibodies or antigen binding fragments thereof, and vectors comprising the isolated polynucleotides. The AXL-targeting antibody provided by the invention can be combined with AXL protein with high affinity, can mediate ADCC to kill tumors, or can be used as a target recognition domain of CART cells to play an anti-tumor role, can be used for preventing or treating tumors, and has a wide application prospect.
Owner:SHANGHAI SINOBAY BIOTECH CO LTD
Monoclonal antibody 9A and application thereof
ActiveCN107987163AHigh potencyStrong specificityImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsAntigen Binding FragmentAntigen binding
The invention discloses a separated binding molecule. The binding molecule is a monoclonal antibody or an antigen binding segment aiming at AXL proteins. In-vitro experiments prove that the monoclonalantibody is capable of being specifically bound with the AXL proteins, has relatively strong affinity activity and is further capable of preventing and stopping diseases caused by the overexpressionof the AXL proteins. According to the research results of the invention, on one hand a new method is provided for clinical diagnosis, and on the other hand, a candidate drug is provided for the clinical treatment of diseases such as tumor relevant with overexpression of the AXL proteins.
Owner:HANGZHOU SUMGEN BIOTECH CO LTD
SRM/MRM Assay for the tyrosine-protein kinase receptor UFO (AXL) protein
ActiveUS20170052196A1Improved treatment decision for cancer therapyMass spectrometric analysisMaterial analysis by electric/magnetic meansSelected reaction monitoringSelective reaction
Peptides from the tyrosine-protein kinase receptor UFO protein (AXL) are provided that are particularly advantageous for quantifying the AXL protein directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM) / Multiple Reaction Monitoring (MRM) mass spectrometry. Such biological samples are chemically preserved and fixed and include formalin-fixed tissue / cells, formalin-fixed / paraffin embedded (FFPE) tissue / cells, FFPE tissue blocks and cells from those blocks. A protein digest is prepared from the biological sample and the AXL protein is quantitated in the Liquid Tissue sample by the method of SRM / MRM mass spectrometry by quantitating in the protein sample at least one or more of the peptides described.
Owner:EXPRESSION PATHOLOGY
Antibodies that bind to axl proteins
ActiveUS20180134792A1Biological material analysisImmunoglobulins against cell receptors/antigens/surface-determinantsCancer researchAntibody
Antibodies that bind to AXL protein and variants thereof are described herein. AXL exhibits a distinct and limited expression pattern in normal adult tissue(s), and is aberrantly expressed in the cancers listed in Table I. Consequently, the MAbs of the invention provide a diagnostic composition for the treatment and management of cancer.
Owner:AGENSYS +1
Monoclonal Antibody 9a and Its Application
ActiveCN107987163BHigh potencyStrong specificityImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsAntigen Binding FragmentAntigen binding
The invention discloses a separated binding molecule. The binding molecule is a monoclonal antibody or an antigen binding segment aiming at AXL proteins. In-vitro experiments prove that the monoclonalantibody is capable of being specifically bound with the AXL proteins, has relatively strong affinity activity and is further capable of preventing and stopping diseases caused by the overexpressionof the AXL proteins. According to the research results of the invention, on one hand a new method is provided for clinical diagnosis, and on the other hand, a candidate drug is provided for the clinical treatment of diseases such as tumor relevant with overexpression of the AXL proteins.
Owner:HANGZHOU SUMGEN BIOTECH CO LTD
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com